ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 Nuclear Energy Conference & Expo (NECX)
August 24–27, 2026
Dallas, TX|Hilton Anatole
Latest Magazine Issues
Jun 2026
Jan 2026
2026
Latest Journal Issues
Nuclear Science and Engineering
July 2026
Nuclear Technology
June 2026
Fusion Science and Technology
May 2026
Latest News
MARVEL team shares lessons learned through microreactor development
On June 1 at the American Nuclear Society’s Annual Conference in Denver, Colo., a team from Idaho National Laboratory presented a session titled “Lessons Learned from MARVEL Reactor Fabrication.” The presentation highlighted challenges that arose as they moved from design to manufacturing and assembly, with a focus on reactor part fabrication, Stirling engine implementation, and reactivity control system development.
William A. Neuman, James L. Jones
Nuclear Technology | Volume 92 | Number 1 | October 1990 | Pages 77-92
Technical Paper | Development of Nuclear Gas Cleaning and Filtering Techniques / Fission Reactor | doi.org/10.13182/NT90-A34488
Articles are hosted by Taylor and Francis Online.
A conceptual design of a passively safe reactor facility for boron neutron capture therapy is presented. The facility configuration and its neutronic, thermalhydraulic, and safety issues are addressed in order to demonstrate the deployability of reactor technology for routine patient treatments and advanced research and dosimetry. The reactor has a power level of <10 MW(thermal) and is based on low-enriched UZrH fuel. The reactor facility generates a clean epithermal neutron beam capable of treating deep-seated brain tumors (∼70 mm) in <10 min. The incident fast neutron and gamma-ray contaminants in the beam are 1.8 and 0.4 Gy, respectively, for a 20-Gy therapeutic dose to a deep-seated tumor. With an expected operation schedule of ∼2000 treatment periods per year, the reactor core lifetime is equal to the 30-yr facility lifetime and no refueling is necessary. Five beam ports are available for simultaneous patient treatments allowing between 2000 and 10000 treatments per year with expansion capabilities of at least threefold for 24 h/day operation. The cost per patient treatment is small, about $1000, making the therapy very affordable. The reactor system design includes several passive safety features that allow the reactor to respond in a safe and benign manner in the event of off-normal transients. The response for various instantaneous reactivity insertions is assessed. Results show the reactor can passively respond to a reactivity insertion of 2 $ such that the maximum temperature limits of the fuel are not exceeded.